Product Description
Liraglutide is a derivative of GLP?1 and shares 97% amino acid sequence homology with its parent molecule 9. GLP?1 is a polypeptide incretin hormone secreted by the L?cells of the gastrointestinal tract in response to nutrients in the lumen. It causes a glucose dependent stimulation of insulin secretion 10, reduction in plasma glucagon concentrations 11, delayed gastric emptying 12, appetite suppression 13, 14, and an increase in heart rate (Fig. 1) 15.
Mechanisms of Action: GLP-1 Agonist
Novel Mechanism: No
Modality: Peptide/Protein
Route of Administration: Subcutaneous
FDA Designation: *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Belgium | Bosnia | Brazil | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Mexico | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Vietnam
Approved Indications: None
Company: Novo Nordisk
Company Location: Europe
Company Founding Year: 1923
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Belgium, Canada, China, Denmark, France, Germany, Hong Kong, India, Israel, Malaysia, Mexico, Poland, Portugal, Russia, Spain, Switzerland, United States
Active Clinical Trial Count: 14
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Obesity|Overweight|Type 2 Diabetes
Phase 2: Osteoarthritis, Knee|Synovitis
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT07225829 |
INFLAM MOTION | P2 |
Active, not recruiting |
Synovitis|Osteoarthritis, Knee |
2026-08-28 |
32% |
2026-07-28 |
Primary Completion Date|Primary Endpoints|Treatments|Trial Status |
CTR20250744 |
CTR20250744 | P3 |
Completed |
Type 2 Diabetes |
2026-06-24 |
2026-07-20 |
Primary Completion Date|Study Completion Date|Treatments|Trial Status |
|
NCT07225816 |
Injected | P1 |
Recruiting |
Obesity |
2026-12-13 |
12% |
2026-07-22 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
NCT05268237 |
BIOL-001 | P2 |
Recruiting |
Type 2 Diabetes |
2025-12-01 |
2025-02-07 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
|
2018-002425-34 |
2018-002425-34 | P2 |
Completed |
Type 2 Diabetes |
2024-12-13 |
2025-05-06 |
Primary Completion Date|Study Completion Date|Treatments|Trial Status |
|
2023-508504-38-00 |
NN8022-4392 | P3 |
Active, not recruiting |
Obesity |
2027-01-15 |
2025-05-02 |
Treatments |
|
NCT06559722 |
THDB0213L03 | P3 |
Not yet recruiting |
Type 2 Diabetes |
2025-10-01 |
2024-08-20 |
||
CTR20242558 |
CTR20242558 | P3 |
Completed |
Type 2 Diabetes |
2025-08-29 |
2026-05-03 |
Primary Completion Date|Study Completion Date|Treatments|Trial Status |
|
2020-000546-34 |
2020-000546-34 | P3 |
Active, not recruiting |
Obesity |
2023-12-03 |
44% |
2022-03-13 |
Treatments |
NCT04775082 |
SCALE KIDS | P3 |
Active, not recruiting |
Obesity |
2023-08-01 |
44% |
2023-09-09 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
CTR20201449 |
CTR20201449 | P3 |
Active, not recruiting |
Obesity|Overweight |
None |
2025-04-29 |
Patient Enrollment|Start Date|Treatments|Trial Status |
|
CTR20211086 |
CTR20211086 | P3 |
Recruiting |
Type 2 Diabetes |
None |
2025-04-29 |
Patient Enrollment|Start Date|Treatments|Trial Status |
|
NCT06439056 |
NEX-22-01 | P1 |
Completed |
Type 2 Diabetes |
2025-07-18 |
2025-09-24 |
Primary Endpoints |
|
CTR20241536 |
CTR20241536 | P1 |
Completed |
Type 2 Diabetes |
2024-06-25 |
2025-04-29 |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
04/21/2026 |
News Article |
Lexaria Expects Oral GLP-1 Pills to Generate Billions in New Industry Sales |
|
04/17/2026 |
News Article |
Annals of Internal Medicine presents breaking scientific news at ACP's Internal Medicine Meeting 2026 |
|
04/15/2026 |
News Article |
Svetlana Mojsov, one of the Scientists behind Ozempic, and Mathematician Carlos Kenig, who Decoded Laws of Motion, Honored as King Faisal Prize 2026 Laureates |
|
04/07/2026 |
News Article |
Lexaria Applauds Eli Lilly's Foundayo(TM) Drug Approval |